Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call

Core Insights - Idorsia will host a live investor Q&A webcast and conference call to discuss the role of TRYVIO™ (aprocitentan) in treating difficult-to-control hypertension, marking it as the first and only therapy targeting the endothelin pathway [1] Group 1 - The event is scheduled for September 8, 2025, at 16:00 CEST / 15:00 BST / 10:00 EDT, starting with a presentation by senior management followed by a Q&A session [1] - The live webcast will be accessible via the Idorsia website, providing both audio and slides for participants [2] - Analysts wishing to ask questions must register in advance through a specified link, and a replay of the webcast will be available approximately 60 minutes after the call [3]